Visit IQVIA

IQVIA Core Diabetes Model

IQVIA CORE Diabetes Model update

Dear IQVIA Core Diabetes Model User,

Please be aware that, as detailed in a previous communication distributed on 21st February 2019, the IQVIA Core Diabetes Model will be migrating to the online IQVIA E360 platform. To facilitate this migration, the model will be inaccessible from 5:00pm BST on Friday 15th March until 1:00pm BST on Tuesday 19th March.

At this time you will receive an e-mail with a user guide attached as well as instructions to log on to the new platform. Additionally, instructions will be posted on the current IQVIA Core Diabetes Model webpage detailing the process of gaining access to E360. Information regarding the E360 platform can be found via this link: https://www.iqvia.com/solutions/real-world-value-and-outcomes/enterprise-technology-and-analytics/e360.

If you happen to have any questions or concerns about this, please do not hesitate to contact us at CDMteam@uk.imshealth.com or mark.lamotte@iqvia.com. Thank you very much for your time.

Kind Regards,

Mark Lamotte for
The IQVIA Core Diabetes Model Team

IQVIA CORE Diabetes Model update

Dear IQVIA CORE Diabetes model users,

IQVIA are pleased to inform all users that we will release the updated 64bit version of IQVIA CORE Diabetes Model (CDM) version 9.0 and version 8.5 by March 17 2017.

The transition to the updated 64 bit CDM infrastructure is part of a continued development programme to ensure that the CDM is hosted and processed on current state-of-the-art technology and software. This upgrade is associated with a number of benefits which are outlined below.

Simulation time – The number of simultaneous simulations that can be processed on the simulation severer system has been increased more than threefold which will considerably reduce the overall waiting time until simulation results can be accessed.

Stability – Recently an increasing number of simulation crashes have been observed (simulations being interrupted during execution and requiring restart) which contributed to the elongation of waiting time until outcomes can be accessed. With the upgrade to the new system it is expected that the stability of simulation processes will be substantially improved.

Security – The technologies used by 64bit CDM allow improvement to the security of the environment on which new CDM system is built. It will allow the development and deployment of resolutions to newly discovered threats as well as ensuring improved safety and integrity of data. SSL encryption of all communication between the user and web interface mean that all sensitive settings and simulation data will remain protected from outside interference and theft.

With this background information we kindly advise all CDM users to start using the new 64bit CDM versions as soon as possible.

The following URL link to the new 64bit CDM version can be used:

64bit CDM
CDM v9.0 and CDM v8.5: https://www.core-diabetes.com

The new versions will be fully equivalent to the current (32 bit) versions with the below exceptions:

  • Due to the change to the 64bit infrastructure, the randomness of simulations has changed which means that simulations that are executed on the new system will present slight (random) deviations towards outcomes generated on the current versions. The magnitude of random variability is dependent on the simulation size (i.e. declines with increasing number of patients and/or bootstrap iterations included).
  • The web interface appearance has changed slightly. Since the upgrade to 64 bit required a reimplementation of the web code, we took advantage of this update to change particular features which are explained in the attached update guide.
To avoid having to replicate all the work you have done for example for an ongoing submission, the 32Bit version remains still available for some time.

To access the 32bit versions, please use the following URL links:
32bit CDM
CDM v9.0: http://www.core-diabetes.com:8080/login.asp
CDM v8.5: http://www.core-diabetes.com:8080/CDM2012/login.asp

IQVIA CORE Diabetes Model User Group Forum

Dear CDM user,

The IQVIA Core Diabetes Model team will be at ISPOR in Milan in November, if you would like to attend a workshop on Sunday 8th November to find out more about the model please contact Mike Gains

Meeting Agenda

  • Introduction to version 9.0 of the model
  • Hypoglycaemic event module
  • New type 2 risk equations
  • Completely new Type 1 inputs based on new equations
  • NICE comments on version 8.5 and how they are addressed in version 9
  • Assessing the impact of BMI on cost-effectiveness
  • FAQ’s on the CDM

If you already use the model and have any questions regarding the analyses you are running please send all your questions and remarks to mlamotte@be.imshealth.com

Mark Lamotte
Senior Principal - Cardiologist
Real-World Evidence Solutions & HEOR
IQVIA

CDM USER FORUM - ISPOR Milan 2015

IQVIA CORE Diabetes Model Version 9.0

Dear user,

On July 13 2015 we launched version 9.0 of the CDM.
This updated version includes additional risk equation, a new module on hypoglycaemia, a complete rework of type 1 diabetes including the most recent available information, as well as a revised user interface.

If you want to use version 9.0 please click here www.core-diabetes.com

If you want to continue using version 8.5 please click here www.core-diabetes.com/cdm2012

Version 9.0 has been thoroughly tested however this does not exclude that there are still errors. Please e-mails us at info_CDM@imshealth.com if you face any issue.

Looking forward to hear from you,

Mark Lamotte, MD

Scientific Leader CDM

A tool for policy analysis and reimbursement strategy in diabetes

The IQVIA CORE Diabetes Model (IQVIA CDM) simulates disease progression in both type 1 and type 2 diabetes. The model is a tool that can be used to explore economic value over the course of a product’s lifecycle. Potential applications include identification of clinical development priorities, pricing evaluation, health technology assessment and post-launch market access support. The IQVIA CDM is a computer simulation model designed to take surrogate endpoints and translate them in to long term health economic outcomes:

The IQVIA CDM is the most widely adopted economic model in diabetes available to users from academia, and health care industries, as well as health care payers and decision makers.

  • The model has undergone an extensive validation process.
  • It is continually updated to include the latest clinical and epidemiological data as well as to implement functional improvements.
  • Results from the model have been widely published, with over 80 peer-reviewed publications.
  • 7 of the 10 largest diabetes drug and device manufacturers are using the CDM.


The IQVIA Core Diabetes Model will be made available again on the IQVIA E360 platform at 1:00pm BST on Tuesday 19th March 2019. Thank you for your patience during this process.

Users will be able to gain access to the E360 platform by clicking the E360 logo, found where the CDM log-in link was formerly located on the CDM webpage.

At this point, clicking “Forgotten your Login?” and entering the email address associated with your CDM user account will lead to an access credential retrieval email being sent to you. This will provide everything necessary to obtain access.

If your email is for any reason invalid, or you lack a registered email for the CDM, please do not hesitate to contact us at CDMTeam@imshealth.com. Thank you very much for your time.

Find out how our team can help.

Additional Information

IQVIA CORE Diabetes Model is an IQVIA online application.
Click here for the HEOR & Real-World Evidence homepage.
This site is only supported with latest internet browser technology (HTML5, CSS3 & Jquery inside).

Privacy   |   Terms of Use    Copyright © 2017 IQVIA Incorporated. All rights reserved.